Introduction {#S0001}
============

Colorectal cancer (CRC) is the third highest cause of cancer deaths worldwide.[@CIT0001],[@CIT0002] The time of diagnosis directly influences the overall survival rate of patients. The five-year survival rates are estimated to decrease 12.5% after the occurrence of metastasis vs for localized cancer. Histological examination of tumor tissue is the gold standard for diagnosis, but is invasive, time-consuming, and nonrepeatable over time. There is a need for new methods that are simple, non-invasive, and inexpensive to provide clear clinical evidence and improve early detection or predict a response to treatment.[@CIT0003],[@CIT0004]

Serum biomarkers such as carcinoembryonic antigens (CEAs) and carbohydrate antigen 19-9 (CA19-9) along with multi-target stool DNA tests represent the concrete implementation of non-invasive methods for CRC screening[@CIT0005],[@CIT0006] There is urgent need for more reliable molecular markers that demonstrate the heterogeneity of cancer cells during progression. The use of biological fluids as sources of nucleic acid-biomarkers for liquid biopsies in oncology has clinical promise[@CIT0007],[@CIT0008] Molecular characterization of cancer signatures also can provide relevant information for personalized treatment of tumors.[@CIT0009],[@CIT0010] Circulating tumor cells (CTCs) and exosomes are shed from a tumor mass and enter the bloodstream. They can provide a metastatic niche for the invasion and migration of a tumor, so detection of their markers is critical.[@CIT0011]

Ashworth et al, first identified CTCs as valuable indicators of cancer progression.[@CIT0012] CTCs detach from the primary tumor, intravasate into the bloodstream, evade immune detection, survive and extravasate into the microvessels of target tissue to establish a micro-metastatic niche.[@CIT0013] They have been identified in many cancers, including colon cancer. CTCs in the bloodstream may exist as single cells with a different EMT phenotypes or as clusters that bind to platelets or macrophages or are reactivated as stromal cells.[@CIT0014],[@CIT0015] The presence and number of CTCs before and during treatment are a strong independent predictor of shorter progression-free survival and overall survival of CRC patients.[@CIT0016] In spite of their advantages, researchers believe that the most challenging obstacles related to research on CTCs are their extremely low numbers, short lifetimes, fragility, and their heterogeneity and plasticity. The investigation of specific and reliable markers for their detection or isolation is an undeniable issue.[@CIT0017]

Extracellular vesicles (EVs) generally include microvesicles (100--350 nm), apoptotic bodies (500--1000 nm), and exosomes (30--150 nm).[@CIT0018] Exosomes are nanovesicles with membrane-bound phospholipids which introduced and confirmed by Pan et al,[@CIT0019] and are actively secreted by mammalian cells into body fluids such as urine, plasma, and saliva. Exosomal cargo includes lipids, proteins, DNA, and RNA (mRNA, miRNA, long non-coding RNA) that are selected according to their roles. Exosomes involved in many biological processes, especially intercellular communication, establish a premetastatic niche by carrying oncogenic elements that suppress host immune responses.[@CIT0020]

Exosomes are abundant, have high half-lives and are released by most cells. This is in contrast with CTCs, which are tumor specific, rare, fragile, have a short life and are difficult to isolate. It is possible to design a molecular marker common between the exosomes and CTCs for better understanding of the metastasis process. American Society of Clinical Oncology suggests circulating exosomes may provide an alternative platform for monitoring disease progression as opposed to CTCs.[@CIT0021] Several ongoing studies have aimed at quantifying a stress protein or other biomarkers in the blood and urine for monitoring and early diagnosis of malignant solid tumors (<https://clinicaltrials.gov>). The current analytical review is the first to explore similar molecular mechanisms and pathways between CTCs and Exosomes. In this systematic review, all molecular mechanisms that can potentially apply to the diagnosis and prognosis of CRC using CTCs and exosomes are discussed.

Materials and methods {#S0002}
=====================

Search strategy for literature mining {#S0002-S2001}
-------------------------------------

Observational studies evaluating the expression of circulating CRC cells and exosomes markers from 1980 to July 24, 2019 were electronically searched for in the PubMed, Scopus, Embase, and ISI Web of Science databases. The search syntax was modified for each database in accordance with their rules, the Mesh terms and keywords as listed in detail in [Table 1](#T0001){ref-type="table"}.Table 1Search strategy of CTC and exosome in colorectal cancerSearch strategyNo. of papers2019 24 July**SCOPUS**1(TITLE-ABS-KEY (cecum OR colon OR sigmoid OR rectum OR anal)) AND (TITLE-ABS-KEY ((neoplasm OR cancer OR tumor OR tumors OR carcinoma))) OR (TITLE-ABS-KEY ((colorectal AND neoplasms OR crc)))258,5692(TITLE-ABS-KEY (circulating AND tumor AND cell)) OR (TITLE-ABS-KEY (circulating AND neoplastic AND cells)) OR (TITLE-ABS-KEY (neoplasm AND micro-metastasis)) OR (TITLE-ABS-KEY (ctc OR ctm OR dtc))60,0123((TITLE-ABS-KEY (gene AND expression AND profiling)) OR (TITLE-ABS-KEY (messenger AND rna)) OR (TITLE-ABS-KEY (rna OR transcriptome OR mrna))) AND ((TITLE-ABS-KEY (early AND diagnosis)) OR (TITLE-ABS-KEY (early AND detection)) OR (TITLE-ABS-KEY (prognosis OR diagnosis OR biomarkers OR screening OR diagnostic OR prognosis OR prognostic)))209,2074(TITLE-ABS-KEY (extracellular AND vesicle)) OR (TITLE-ABS-KEY (cell-derived AND microparticles)) OR (TITLE-ABS-KEY (extracellular AND vesicles)) OR (TITLE-ABS-KEY (ev OR microvesicle OR exosomes))274,6151 & 2 & 3(((TITLE-ABS-KEY (gene AND expression AND profiling)) OR (TITLE-ABS-KEY (messenger AND rna)) OR (TITLE-ABS-KEY (rna OR transcriptome OR mrna))) AND ((TITLE-ABS-KEY (early AND diagnosis)) OR (TITLE-ABS-KEY (early AND detection)) OR (TITLE-ABS-KEY (prognosis OR diagnosis OR biomarkers OR screening OR diagnostic OR prognosis OR prognostic)))) AND ((TITLE-ABS-KEY (circulating AND tumor AND cell)) OR (TITLE-ABS-KEY (circulating AND neoplastic AND cells)) OR (TITLE-ABS-KEY (neoplasm AND micrometastasis)) OR (TITLE-ABS-KEY (ctc OR ctm OR dtc))) AND ((TITLE-ABS-KEY (cecum OR colon OR sigmoid OR rectum OR anal)) AND (TITLE-ABS-KEY ((neoplasm OR cancer OR tumor OR tumors OR carcinoma))) OR (TITLE-ABS-KEY ((colorectal AND neoplasms OR crc)))) AND (LIMIT-TO (LANGUAGE, "English")) AND (LIMIT-TO (SRCTYPE, "j")) AND (LIMIT-TO (DOCTYPE, "ar") OR LIMIT-TO (DOCTYPE, "no") OR LIMIT-TO (DOCTYPE, "le")) AND (LIMIT-TO (EXACTKEYWORD, "Human"))1181 & 2 & 4(((TITLE-ABS-KEY (gene AND expression AND profiling)) OR (TITLE-ABS-KEY (messenger AND rna)) OR (TITLE-ABS-KEY (rna OR transcriptome OR mrna))) AND ((TITLE-ABS-KEY (early AND diagnosis)) OR (TITLE-ABS-KEY (early AND detection)) OR (TITLE-ABS-KEY (prognosis OR diagnosis OR biomarkers OR screening OR diagnostic OR prognosis OR prognostic)))) AND ((TITLE-ABS-KEY (extracellular AND vesicle)) OR (TITLE-ABS-KEY (cell-derived AND microparticles)) OR (TITLE-ABS-KEY (extracellular AND vesicles)) OR (TITLE-ABS-KEY (ev OR microvesicle OR exosomes))) AND ((TITLE-ABS-KEY (cecum OR colon OR sigmoid OR rectum OR anal)) AND (TITLE-ABS-KEY ((neoplasm OR cancer OR tumor OR tumors OR carcinoma))) OR (TITLE-ABS-KEY ((colorectal AND neoplasms OR crc)))) AND (LIMIT-TO (DOCTYPE, "ar") OR LIMIT-TO (DOCTYPE, "ip")) AND (LIMIT-TO (EXACTKEYWORD, "Human")) AND (LIMIT-TO (LANGUAGE, "English")) AND (LIMIT-TO (SRCTYPE, "j"))37**PUBMED**1((Colorectal Neoplasms\[Title/Abstract\] OR "Colorectal Neoplasms"\[Mesh\] OR CRC\[Title/Abstract\]) OR (("Cecum"\[Mesh\] OR "Colon"\[Mesh\] OR "Colon, Sigmoid"\[Mesh\] OR "Rectum"\[Mesh\] OR "Anal Canal"\[Mesh\]) AND ("Neoplasms"\[Mesh\] OR "Carcinoma"\[Mesh\])) OR ((cecum\[Title/Abstract\] OR colon\[Title/Abstract\] OR sigmoid\[Title/Abstract\] OR rectum\[Title/Abstract\] OR anus\[Title/Abstract\]) AND (neoplasm\[Title/Abstract\] OR cancer\[Title/Abstract\] OR tumor\[Title/Abstract\] OR tumors\[Title/Abstract\] OR carcinoma\[Title/Abstract\]))251,8192("Neoplastic Cells, Circulating"\[Mesh\] OR Circulating Tumor Cell\[Title/Abstract\] OR "Neoplasm Micrometastasis"\[Mesh\] OR CTC\[Title/Abstract\] OR CTM\[Title/Abstract\] OR DTC\[Title/Abstract\]20,0013("Prognosis"\[Mesh\] OR "Diagnosis"\[Mesh\] OR "Early Diagnosis"\[Mesh\] OR "Early Detection of Cancer"\[Mesh\] OR "Biomarkers, Tumor"\[Mesh\]) OR ("screening"\[Title/Abstract\] OR "early detection"\[Title/Abstract\] OR "Diagnosis"\[Title/Abstract\] OR "Diagnostic"\[Title/Abstract\] OR "Prognosis"\[Title/Abstract\] OR "Prognostic"\[Title/Abstract\]) AND ("RNA, Messenger"\[Mesh\] OR "RNA"\[Mesh\] OR "Transcriptome"\[Mesh\] OR "Gene Expression Profiling"\[Mesh\] OR "mRNA" OR "RNA" OR "Transcriptome" OR "gene expression profiling")376,2694("extracellular vesicles"\[Mesh\] OR "Cell-Derived Microparticles"\[Mesh\] OR "EV" OR "microvesicle" OR "extracellular vesicle" OR "Exosomes"\[Mesh\] OR Exosome)41,8311 & 2 & 3Search ((((((Colorectal Neoplasms\[Title/Abstract\] OR "Colorectal Neoplasms"\[Mesh\] OR CRC\[Title/Abstract\]) OR (("Cecum"\[Mesh\] OR "Colon"\[Mesh\] OR "Colon, Sigmoid"\[Mesh\] OR "Rectum"\[Mesh\] OR "Anal Canal"\[Mesh\]) AND ("Neoplasms"\[Mesh\] OR "Carcinoma"\[Mesh\])) OR ((cecum\[Title/Abstract\] OR colon\[Title/Abstract\] OR sigmoid\[Title/Abstract\] OR rectum\[Title/Abstract\] OR anus\[Title/Abstract\]) AND (neoplasm\[Title/Abstract\] OR cancer\[Title/Abstract\] OR tumor\[Title/Abstract\] OR tumors\[Title/Abstract\] OR carcinoma\[Title/Abstract\])))) AND (("Neoplastic Cells, Circulating"\[Mesh\] OR Circulating Tumor Cell\[Title/Abstract\] OR "Neoplasm Micrometastasis"\[Mesh\] OR CTC\[Title/Abstract\] OR CTM\[Title/Abstract\] OR DTC\[Title/Abstract\])) AND ((("Prognosis"\[Mesh\] OR "Diagnosis"\[Mesh\] OR "Early Diagnosis"\[Mesh\] OR "Early Detection of Cancer"\[Mesh\] OR "Biomarkers, Tumor"\[Mesh\]) OR ("screening"\[Title/Abstract\] OR "early detection"\[Title/Abstract\] OR "Diagnosis"\[Title/Abstract\] OR "Diagnostic"\[Title/Abstract\] OR "Prognosis"\[Title/Abstract\] OR "Prognostic"\[Title/Abstract\]) AND ("RNA, Messenger"\[Mesh\] OR "RNA"\[Mesh\] OR "Transcriptome"\[Mesh\] OR "Gene Expression Profiling"\[Mesh\] OR "mRNA" OR "RNA" OR "Transcriptome" OR "gene expression profiling")))) Filters: Humans; English1641 & 2 &4Search (((((((Colorectal Neoplasms\[Title/Abstract\] OR "Colorectal Neoplasms"\[Mesh\] OR CRC\[Title/Abstract\]) OR (("Cecum"\[Mesh\] OR "Colon"\[Mesh\] OR "Colon, Sigmoid"\[Mesh\] OR "Rectum"\[Mesh\] OR "Anal Canal"\[Mesh\]) AND ("Neoplasms"\[Mesh\] OR "Carcinoma"\[Mesh\])) OR ((cecum\[Title/Abstract\] OR colon\[Title/Abstract\] OR sigmoid\[Title/Abstract\] OR rectum\[Title/Abstract\] OR anus\[Title/Abstract\]) AND (neoplasm\[Title/Abstract\] OR cancer\[Title/Abstract\] OR tumor\[Title/Abstract\] OR tumors\[Title/Abstract\] OR carcinoma\[Title/Abstract\])))) AND ((("Prognosis"\[Mesh\] OR "Diagnosis"\[Mesh\] OR "Early Diagnosis"\[Mesh\] OR "Early Detection of Cancer"\[Mesh\] OR "Biomarkers, Tumor"\[Mesh\]) OR ("screening"\[Title/Abstract\] OR "early detection"\[Title/Abstract\] OR "Diagnosis"\[Title/Abstract\] OR "Diagnostic"\[Title/Abstract\] OR "Prognosis"\[Title/Abstract\] OR "Prognostic"\[Title/Abstract\]) AND ("RNA, Messenger"\[Mesh\] OR "RNA"\[Mesh\] OR "Transcriptome"\[Mesh\] OR "Gene Expression Profiling"\[Mesh\] OR "mRNA" OR "RNA" OR "Transcriptome" OR "gene expression profiling")))) AND ((("extracellular vesicles"\[Mesh\] OR "Cell-Derived Microparticles"\[Mesh\] OR "EV" OR "microvesicle" OR "extracellular vesicle" OR "Exosomes"\[Mesh\] OR Exosome))))) Filters: Humans; English66**Embase**1(cecum OR sigmoid OR rectum OR anal) AND (neoplasm OR cancer OR tumor OR tumors OR carcinoma) OR "colorectal cancer" OR crc323,3842ctc OR ctm OR dtc OR (circulating AND neoplastic AND cells) OR (circulating AND tumor AND cell) OR (neoplasm AND "micro-metastasis")54,4233(early AND diagnosis) OR (early AND detection) OR biomarkers OR screening OR diagnostic OR prognosis OR prognostic) AND (messenger AND rna) OR (gene AND expression AND profiling) OR mrna OR transcriptome101,3054"membrane microparticle" OR "exosome"25,6141 & 2 & 3\#1 AND \#2 AND \#3 AND (\[article\]/lim OR \[article in press\]/lim OR \[letter\]/lim OR \[note\]/lim) AND \[english\]/lim AND \[humans\]/lim AND \[embase\]/lim1351 & 2 & 4\#1 AND \#2 AND \#4 AND (\[article\]/lim OR \[article in press\]/lim OR \[letter\]/lim OR \[note\]/lim) AND \[english\]/lim AND \[humans\]/lim AND \[embase\]/lim52**Web of Science**1TI=(Cecum OR Colon OR Colon Sigmoid OR Rectum OR Anal) AND (neoplasm OR cancer OR tumor OR tumors OR carcinoma) OR TI=(Colorectal Neoplasms OR CRC)43,0392TS=(Circulating Neoplastic Cells OR Circulating Tumor Cell OR Neoplasm Micrometastasis OR CTC OR CTM OR DTC)44,3393TS=(Prognosis OR Diagnosis OR Early Diagnosis OR Early Detection OR Biomarkers OR screening OR Diagnostic OR Prognosis OR Prognostic) AND TS=(Messenger RNA OR RNA OR Transcriptome OR Gene Expression Profiling OR mRNA)138,1334TS=(extracellular vesicles OR Cell-Derived Microparticles OR EV OR microvesicle OR extracellular vesicle OR Exosomes)212,0891 & 2 & 3\#1 AND \#2 AND \#3 (\#8 AND \#7 AND \#3) AND LANGUAGE: (English) AND DOCUMENT TYPES: (Article)191 & 2 & 4\#1 AND \#2 AND \#4 AND (\#8 AND \#7 AND \#3) AND LANGUAGE: (English)15[^1]

The authors (S. Vafaei and F. Fattahi) searched and identified eligible studies and excluded all irrelevant articles after reviewing the publication titles and abstracts. Duplicate publications were excluded. Discrepancies were resolved between the two reviewers by consensus and by consulting the other authors. Next, the full text of the selected publications was retrieved and fully reviewed. This systematic review has been carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.[@CIT0022]

Publication inclusion criteria {#S0002-S2002}
------------------------------

The inclusion criteria for this systematic review followed the criteria of population, intervention, control, and outcomes. Observational studies (case-control) investigating CTC and exosomes mRNA and gene markers for the diagnosis and prognosis of CRC patient samples were included if they met the following criteria: The article must be published in English and the full text must be available.Studies included those on CRC patient blood samples and human blood for CTC, although tissue or cell lines for exosomes were done because exosomes research is rare and in its initial stages.Expression of mRNA and gene markers in patient specimens or cell lines was detected by established molecular methods.Studies demonstrated the correlation between mRNA profiling using isolation, detection, or validation methods, included sample type and size and other clinical parameters of diagnosis and prognosis, tumor stage and the frequency of estimated marker expression.Study characteristics (first author surname, publication year, and study design) were included.

Publication exclusion criteria {#S0002-S2003}
------------------------------

Exclusion criteria included: Evidence and article on CTC and exosomes covering review articles, seminars, letters, expert opinions, book chapters, meeting records, commentaries, and clinical guidelines.In-vitro or in-vivo experimental studies.Articles that were not published in English.Full text of the article not available.

Exclusion criteria for CTC articles were: Studies performed only on cell lines or tissue samples.Studied housekeeping genes, such as glyceraldehyde-3-phosphate dehydrogenase, actin beta, β2-microglobulin, as they are not specific markers for CTC detection and expressed in all cells.Bioinformatics analysis or data mining without experimental confirmation of the introduced biomarkers.Therapy gaudiness based on the CTC results (perioperative and postoperative) in predicting the clinical outcome, not counting for drug effect on the expression of CTC genes.The study only tested the spiked cell lines in human blood donors and not the actual patients.

In exosome studies, because of the limited data, we reviewed all articles on all markers that were introduced using the cell lines, tissue, or blood, even those only introduced through bioinformatics means without experimental confirmation.

Risk of bias (quality) assessment {#S0002-S2004}
---------------------------------

The quality of each study was assessed using the Newcastle--Ottawa Scale (NOS), a well-known scale for assessing the quality and risk of bias in observational studies.[@CIT0023] NOS gives a score between 0 (minimum) and 9 (maximum). Studies with a NOS score \>6 were considered to be of high quality, making them possible for use as potential moderators in meta-regression analysis.

Statistical analysis {#S0002-S2005}
--------------------

Because the studies included were not sufficiently similar in terms of study design, experimental techniques, and heterogeneity of genetic variants, a meta-analysis was not performed.

Bioinformatics approach to systematic search {#S0002-S2006}
--------------------------------------------

Molecular pathology is a valuable tool in the development of a cancer signature. The initially extracted markers in this article were subjected to STRING (<https://string-db.org/>) for better understanding of the significantly related pathway and secondary data were enriched using the EnrichR (amp.pharm.mssm.edu/Enrichr/) web tool. The GO project provided ontologies to describe the attributes of the gene products in the non-overlapping domains of molecular biology. Molecular function describes activities (such as catalytic or binding activities) at the molecular level. Biological processes describe biological goals accomplished by one or more ordered assemblies of molecular functions. Cellular component describes the locations of subcellular structures and macromolecular complexes.[@CIT0024]

Results {#S0003}
=======

Literature {#S0003-S2001}
----------

The initial search retrieved a total of 607 studies using the search strategy. After primary selection, 497 papers were excluded because they were duplicates, had irrelevant titles or were paper abstracts. Eventually, 110 studies were selected for further evaluation. The schematic of the design and the reasons for exclusions are summarized in [Figures 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"} for CTC and exosomes, respectively.

Clinical applications of CTCs and exosomes in CRC as diagnostic markers {#S0003-S2002}
-----------------------------------------------------------------------

### CTCs {#S0003-S2002-S3001}

Antigen expression of circulating cells and their specific phenotypes affects the progression of cancer and patient survival; thus, the focus was on CTC molecular markers that could lead to the detection of CTC rather than isolation in blood samples. CTC detection methods included real-time polymerase chain reaction (RT-PCR), flow cytometry, fluorescence in situ hybridization, and immunocytochemistry. Isolation methods included Cellsearch, OncoQuick, Filration, magnetic-activated cell sorting, fluorescence-activated cell sorting, Adnatest Colon Cancer Select and Detect, CELLection electrophoresis assay, and microfluidic devices.

When attempting to find more reliable markers for CTCs in CRC cases, 6 out of 39 articles described only CK20 mRNA as the target gene, which is not transcribed in normal hematopoietic cells. It has previously been reported through immunohistochemistry by Moll et al,[@CIT0025]--[@CIT0030] and has been seen in control blood samples through sensitivity assay and sampling,[@CIT0029] in addition to CK20, CA19-9, and CEA, which is used in clinics routinely for CRC detection, also has been introduced as a marker of CTC in CRC. Six of 39 studied examined CEA alone[@CIT0031]--[@CIT0036] or in association with markers such as CK19,[@CIT0037],[@CIT0038] anti-epithelial cell adhesion molecule (EPCAM),[@CIT0039]--[@CIT0043] and transmission electron microscopy (TEM)-8.[@CIT0044]

Wong et al, used a sensitivity assay for the detection of CTCs and nodal metastases using CD44 splice variants as a tumor marker.[@CIT0045] It has been proven that RT-PCR in combination with positive isolation of epithelial tumor cells (addition of Ber-EP4 immunomagnetic) and negative isolation of non-epithelial cells (CD45 immunomagnetic beads used to deplete leukocytes from MNC) could improve detection.[@CIT0030],[@CIT0036] Guanylyl-cyclase C (GCC) is another marker introduced to detect rare epithelial circulating metastatic cancer cells.[@CIT0046]--[@CIT0048]

After 2004, researchers focused on multi-marker panels in literature or data mining as listed in [Table 2](#T0002){ref-type="table"}.[@CIT0049]--[@CIT0056] Besides these, novel markers such as serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), SERPINB5,[@CIT0057] epidermal growth factor receptor (EGFR),[@CIT0058]--[@CIT0060] epithelial cell transforming sequence 2 oncogene (ECT2)[@CIT0061] FAM172A,[@CIT0062] A3 receptor[@CIT0063] have been examined as well as other markers, especially through bioinformatics analysis.[@CIT0064]Table 2The biomarkers which worked for diagnostic of CRC in circulating tumor cellsBiomarkerTechnique of isolation/detection of CTCTechnique of validation/related oneRelated markerCutoffPatients (number/type)Patient stageAuthor/ yearCTCs positive ratePMIDCK20Nested RT-PCR[@CIT0001]SWI 116, HT29 cell spiking--5 mL57 patients, 2 controls[@CIT0002]/BloodI--IV[@CIT0003]Soeth, 1996.[@CIT0028]35%8,797,868Nested RT-PCRA818-4 cell spiking--5 mL39 patients, 12 controls/BloodI--IVSoeth, 1997.[@CIT0027]24%9,242,433RT-PCRHT29 cell spiking, ImmunohistochemistryPBGD5--10 m30 patients, 16 controls/BloodI--IVVlems, 2002.[@CIT0029]30%12,032,226CD45 Immune magnetic beads,/or Ber-EP4 immuno magnetic beadsLS174T cell spiking5 mL40 patients, 10 controls/BloodA--D Dukes[@CIT0003]Guo, 2005.[@CIT0030]80.0%, 82.5%, 72.5%16,048,578RT-PCR----5--10 mL58 patients, 12 controls (abnormal)/BloodA--C DukesZhang, 2005.[@CIT0025]44.8% to 69.0%15,637,763RT-PCRCEA, CK1915 mL57/BloodA--D DukesKatsumata, 2006.[@CIT0026]42.1%17,058,136CEACD45 Immune magnetic beads and/or Ber-EP4 immuno magnetic beadsLS174T cell spiking5 mL25 patients, 10 controls/BloodA--D DukesGuo, 2004.[@CIT0036]25.0%, 83.3%, 88.9%15,490,093RT-PCRSouthern blotting, Colo201, HT1 16, HT29, and HT115 cell spiking--14 mL31 patients, 22 controls/BloodLiver metastasisJonas, 1996.[@CIT0031]58%9,014,772RT-PCRCell spiking--10 mL95 patients, 11 controls/BloodI--IVCastells, 1998.[@CIT0032]41%9,823,981RT-PCRColo201 cell spiking--14 mL24 patients, 9 controls/BloodB, C, D DukesNoh, 1999.[@CIT0033]41.1%10,642,939Nested RT-PCRIn-vivo assayCA19.9, CA72-47 mL51 patients, 40 controls, 18 patients with benign colorectal disease/BloodA--D DukesGuadagni, 2001.[@CIT0034]67%11,289,125RT-PCRHT29 and LS147T cell spiking, Sequence analysisCK2020 mL32 patients, 17controls/Blood--Hampton, 2002.[@CIT0035]36%12,420,218CEA, CK19Semi-quantitative RT-PCRSouthern blotting, SK-BR-3 cell spiking--20 mL33 patients, 26 controls/BloodB--D DukesWong, 2001.[@CIT0038]64%, 88%11,121,864RT-PCR---3 mL53 patients, 25 controls/BloodI--IIISilva, 2002.[@CIT0037]73.6% 32%11,889,075CEA, EPCAM.Adnatest ColonCancerSelect & Detect.Multiplex RT-PCR----50 patients, 40 controls/BloodI--IIIMourtzikou, 2012.[@CIT0041]66%, 6%10.6051/j.issn.2224--3992.2012.01.070EPCAMMultigene qRT-PCR, flow cytometryCK19, CK20, CEA, EGFR.7.5 mL49 patients/BloodI--IVCohen, 2006.[@CIT0039]80%16,945,168EPCAMMicrofluidic device, FISH, CellsearchPan CK, EPCAM2 mL5 patients, 200 controls/bloodWith metastasisGogoi, 2016.[@CIT0040]100%26,808,060EPCAMCTC-chipNCI-H1650 cell spiking--2.7 mL10 patents/BloodAdvancedNagrath, 2007.[@CIT0043]67%18,097,410CEA, TEM-8RT-PCRMAD-MB231 and HT29 cell spiking5 mL40 patients, 40 controls/BloodI--IIIRaeisossadati, 2011.[@CIT0044]55%, 22.5%21,573,768CD44RT-PCRSouthern blotting, HCTl16 cell spiking, Restriction enzyme analysis--15 mL24 patients, 8 controls/BloodB, C DukesWong, 1997.[@CIT0045]16%10.1046/j.1365--2168.1997.02685GCCNested RT-PCR--PSA, PSMA, CEA, CK-19, CK-20, mucin 1, GA733.2.-24 patients, 20 controls/BloodD DukesFava, 2001.[@CIT0046]100%11,579,116Nested Duplex RT-PCRImmuno histochemistryCD3110 mL58 patients, 11controls/BloodB--D DukesTien, 2001.[@CIT0047]52%11,410,499Nested Duplex RT-PCRCCL-220 cell spiking, Immunohistochemistry, Western blotting--10 mL68 patients, 11controls/BloodA--D DukesTien, 2004.[@CIT0048]58.8%15,192,312BMP4, CycD, FAM3D, GPA33, ZPX2, LGALS4, TACSTD1, hTERT, TFF3, TM4SF3, UGT1A9, VIL1, FLJ20127.RT-PCR--B2M10--15 mL16 pooled patients, 16 controls/BloodI--IVSolmi, 2004.[@CIT0049]-, 100%, 100%, -, 100%, 100%, 100%, 100%, 100%, 37.5%, 83%, -, 36.3%15,375,555CK-20, CEA, CK-19, REG4, uPA, TIAM1.RT-PCR------80 patients, 98 controls/BloodI--IIYeh, 2006.[@CIT0050]82.5%, 78.8%, 82.5%, 80.0%, 78.8%, 80.0%.16,391,796TMEM69, RANBP3, PRSS22.Microarray screening,QRT-PCR--10--15 mL2 patients, 4 controls/BloodTNM stageSolmi, 2006.[@CIT0051]\~3-fold17,054,783LOC644844, FABP1, CEACAM5, MUC13, GUCA2A, ABP1, SLC26A3Digital Gene Expression Displayer (DGED), RT-PCR----5 mL8 patients, 9 controls/Blood--Lauriola, 2010.[@CIT0052]--20,596,680SERPINB5qRT-PCRSW480 and T84 cell spikingVSNL1, DPEP1, STC1.5 mL818 patients, 4 IBD, 8 controls, 36 control without malignant disease/BloodTNM stageFindeisen, 2008.[@CIT0057]36%18,949,363CK20, CK19, EGFRMultiplex-PCR----6 mL81 patients, 38 controls/Blood0--IVVaiopoulos, 2014.[@CIT0058]24,922,677CK20,CEA, EGFR,Nested RT-PCR------36 patients, 18 controls/BloodI--IVTeama, 2010.[@CIT0059]41.7, 61.1%, 66.7%10.1016/j.ejmhg.2009.10.001EGFRAdnaTest Colon Cancer Select, AdnaTest Colon Cancer detectCOLO 205, HCC-2998, HCT-116, LoVo, WiDr, CACO-2, HT-29, SW-480, T84, DLD-1, SW-948, SW-1116 cell spiking, IHC, Multiplex RT-PCR.EPCAM, CEA.15 mL20 patients, 22 controls/BloodTNM stageLankiewicz, 2008.[@CIT0060]18%18,936,523ECT2Nested qPCR--CEA4 mL90 patients, 151controls/bloodI--IVChen, 2017.[@CIT0061]--28,362,321FAM172AFiltrationIn situ hybridizationEpCAM, CK8, CK18, CK19, Vimentin, Twist, CD45^−^.5mL45/BloodI--IVCui, 2017.[@CIT0062]75.6%28,618,931A3 adenosine receptorsReal-time RT-PCRImmunocytochemistry--40 mL30/BloodI--IVGessi, 2003.[@CIT0063]--15,355,922TGFβ1, APP, CD9, CLU, ITGB5, LIMS1,RSU 1, TIMP1, TLN1, VCL, BMP6.CELLection^TM^, Agilent expression arraysReal-time RT-PCREPCAM7.5 mL28 patients, 10 controls/BloodPrimary and metastasisBarbazan, 2012.[@CIT0053]22,811,761VIL1, TBX20, GPA33, FAM132ACELLection^TM^Real-time RT-PCR, HT29 and HCT116 cell spikingCD45^−^, EPCAM7.5 mL44 patients, 22 controls/BloodIVBarbazan, 2012.[@CIT0054]77.2%22,304,365TSPAN8, LGALS4.qRT-PCRTRAM based data set meta-analysisEPCAM, SPINK1, COL3A1, CEACAM5, COL1A2, CDH1, CKT18, SLC26A3, REG1A, FN1, LUM, CEACAM6, CK205 mL67 patients, 67 controls/BloodI--IIIRodia, 2016.[@CIT0064]--26,993,598LOXL3, ZEB2, VIL1, TIMP1, CLU, TLN1AdnaTest colon cancer--CD45-, EPCAM, CK 8, 18, and/or 197.5 mL50 patients/BloodAdvancedAlonso-Alconada 2017.[@CIT0055]--29,058,262VIL1, CLU, TIMP1, LOXL3 and ZEB2CELLection^TM^qRT-PCREPCAM7.5 mL50 patients/BloodBarbazan 2012.[@CIT0056]--24,752,533[^2]

Exosomes {#S0003-S2003}
--------

Exosome isolation methods consisted of ultracentrifugation, commercial kits, and a combination of several methods based on their physical, chemical, immunological, and molecular markers. Characterization of exosomes was also achieved based on morphology, such as with scanning electron microscopy and TEM, based on size, such as with dynamic light-scattering and nanoparticle tracking assay or based on molecular profiling through conventional enzyme-linked immunosorbent assay, polymerase chain reaction, and Western blotting.

Exosomes carry molecular markers such as DNA, RNA, and proteins. Many reports indicate that exosomes contain miRNAs;[@CIT0065]--[@CIT0068] moreover, blood EVs contain a substantial fraction of intact mRNAs[@CIT0069]--[@CIT0072] and a large number of assembling spliced junctions-circRNAs[@CIT0073] and long non-coding RNAs.[@CIT0072],[@CIT0074],[@CIT0075] Exosomal proteins belong to the following functional groups: tetraspanins, including CD63 antigen (CD63), CD9 antigen (CD9), CD81 antigen (CD81), heat shock proteins (HSC70 and HSC90), and endosomal sorting complexes required for transport proteins such as Alix and TSG101, found in a wide range of exosomes.[@CIT0076] The size of the extra vesicles varied and could influence gene expression. Larger vesicles (\<100 nm) exhibited the greatest amount of EPCAM in extracted exosomes of HCT116 (CRC cell line) cells.[@CIT0077] The level of glypican-1 was evaluated in exosomes of patients before and after surgical treatment.[@CIT0078]

KRTAP5-4 and MAGEA3 mRNA in the serum of patients could be used as diagnostic biomarkers to detect CRC.[@CIT0079] Ct-OATP1B3 mRNA was present in EVs derived from HCT116, HT-29, and SW480 cells that were declared to be serum-based CRC biomarkers,[@CIT0080] Huang et al, introduced UBC, H3F3A, HIST2H2AA3, AKT3, and HSPA1B as hub genes in bioinformatic analysis to serve as diagnostic markers and therapeutic targets of CRC in the future.[@CIT0081] [Table 3](#T0003){ref-type="table"} shows all of these results.Table 3The biomarkers which worked for diagnostic of CRC in ExosomeBiomarkerTechnique of exosome isolationTechnique of exosome validationTechnique of markers detection or validationRelated markerPatients (number/type)Patient stageAuthor/year:PMIDKRTAP5-4, MAGEA3Centrifugation syringe filterTEM, NTA, light microscopeBioinformatic Analysis, RT-PCRlncRNA30 patients, 30 control/BloodI--IVDong, 2016.[@CIT0079]27,197,301GPC1ExoCapTMTEM, Flow cytometry, Western blottingFlow cytometry, Western blot analysismiR‐96‐5p, miR‐149, miR‐182‐5p102 patients, 89 control/tissue and Blood, Cell line (HT‐29 & HCT‐116), MouseI--IILi, 2017.[@CIT0078]28,233,416EPCAMPEGELISA, SEMqRT-PCR, SEM, DLS, ELISA--HCT‐116 Cell line--Manri, 2016.[@CIT0077]27,917,441UBC, H3F3A, HIST2H2AA3, AKT3, HSPA1BGSE100206, GSE100063, GSE32323 (Bioinformatic Analysis)--29 patients, 49 control/tissue and Blood--Huang, 2018.[@CIT0081]doi: 10.21037/tcr.2018.05.32OATP1B3Exosome Isolation kit (Thermo Fisher Scientific), PVDF filter and Differential centrifugationTEM, Western blottingqRT-PCR, Western blotting--HCT116, HT-29, and SW480 cell line, Blood of Mouse--Morio, 2018.[@CIT0080]29,491,222[^3]

Clinical applications of CTCs and exosomes in CRC as prognostic markers {#S0003-S2004}
-----------------------------------------------------------------------

### CTCs {#S0003-S2004-S3001}

Many researchers had discovered prognostic markers related to CRC as a beneficial tool for the detection of CTC. Five papers reported only CK20-positive as a prognostic marker. It caused significantly shorter survival in patients than the CK 20-negative marker.[@CIT0082]--[@CIT0086] However, some studies emphasized only on CEA as a marker (five articles)[@CIT0087]--[@CIT0091] and several studies also introduced both CK20 and CEA as prognostic markers.[@CIT0092]--[@CIT0096] In most articles, CK20 and/or CEA were accompanied by markers such as CK19,[@CIT0097]--[@CIT0102] GCC,[@CIT0096],[@CIT0103],[@CIT0104] Prominin 1 (CD133),[@CIT0095],[@CIT0100],[@CIT0105],[@CIT0106] EPCAM,[@CIT0107]--[@CIT0109] survivin,[@CIT0110],[@CIT0111] ProtM,[@CIT0112] mucin 1 (MUC 1),[@CIT0105] and mucin 2 (MUC 2),[@CIT0099] and telomerase reverse transcriptase (hTERT).[@CIT0101],[@CIT0113],[@CIT0114]

Douard et al, showed that the expression of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; formerly CEA)[@CIT0102],[@CIT0115] and CEACAM7 (formerly CGM2)[@CIT0115],[@CIT0116] was more sensitive than use of a single marker in detecting CTCs, in contrast to the other studies, Bessa et al, showed that assessment of CTCs using RT-PCR CEA before surgery does not have prognostic value for CRC patients.[@CIT0117]

Some articles examined markers that had been investigated previously, such as EGFR,[@CIT0107],[@CIT0118]--[@CIT0121] Plastin3),[@CIT0122],[@CIT0123] anterior gradient-2,[@CIT0102],[@CIT0124],[@CIT0125] leucine-rich repeat-containing-G-protein-coupled receptor 5,[@CIT0102],[@CIT0109],[@CIT0126]--[@CIT0128] double cortin-like kinase 1,[@CIT0109],[@CIT0127] twist family bHLH transcription factor 1,[@CIT0110],[@CIT0129] and aldehyde dehydrogenase 1[@CIT0105],[@CIT0129] as prognostic markers in CRC through CTC.

Gradilone et al, assessed CK19 (75%), CK20 (8%), and EGFR (25%) expression in CTCs of some malignant tumors, including CRC samples, by RT-PCR followed by southern blot hybridization. They reported no correlation between prognostic values of CTCs and clinical manifestations of CRC.[@CIT0130]

Histone-like protein (HLM),[@CIT0120] tenascin C,[@CIT0121] aquaporin (AQP5),[@CIT0131] plakophilin 3, tyrosinase, prostate-specific antigen),[@CIT0132] universal MAGE-A,[@CIT0133] disheveled segment polarity protein 1 (DVL1),[@CIT0134] CD47,[@CIT0135] and CD44 variant exon 9 (CD44v9)[@CIT0136] were proposed as markers in a smaller number of articles. The heterogeneity of CTC markers led some researchers to focus on multi-marker panels in data mining as listed in [Table 4](#T0004){ref-type="table"}.[@CIT0101],[@CIT0105],[@CIT0109],[@CIT0110],[@CIT0114],[@CIT0125],[@CIT0129],[@CIT0137]--[@CIT0139]Table 4The biomarkers which worked for prognostic of CRC in circulating tumor cellsBiomarkerTechnique of isolation/detection of CTCTechnique of validation/related oneRelated markerCutoffPatients (number/type)Patient stageAuthor/yearCTCs positive ratePMIDCK20RT-PCRColo205 cell spiking--2 mL8 patients, 3 controls/BloodIII--IVFunaki, 1997.[@CIT0084]36%9,048,967RT-PCRHT29 cell spiking--10 cells/2 mL26 patients, 12 controls/BloodB, C Dukes stageWyld, 1998.[@CIT0082]48%9,645,353RT-PCR----10 mL108 patients, 38 controls/BloodI--IVHinz, 2012.[@CIT0083]25%22,395,998qRT-PCR----5 mL95 patients, 23 controls/BloodI--IVSamija, 2013[@CIT0085]--23,558,939RT-PCR----5 mL95 patients, 23 controls/BloodI--IVKust, 2016.[@CIT0086]--27,144,776CEART-PCRSouthern blot hybridization--7 mL69 patients, 16 controls/BloodI--IVPiva, 2000.[@CIT0087]34%11,096,345qRT-PCRCOLM-2 cell spiking--5--7 mL99 patients, 20 controls/BloodI--IIIIto, 2002.[@CIT0088]44.4%12,065,095RT-PCR5 mL108 patients, 76 controls/BloodIII--IV[Kanellos]{.ul}, 2006.[@CIT0089]11.1%16,788,936Membrane arraysRT-PCR--4 mL141 patients/BloodII--IIILu, 2011.[@CIT0090]33.3%21,343,933CellSearch (EPCAM)CellTracks® Analyzer IICD45**^−^**7.5 mL20 patients/BloodI--IIIThorsteinsson, 2011.[@CIT0091]5%21,378,346CK20, CEA.RT-PCRColo320 cell spiking--10 mL52 patients, 10 controls/BloodI--IVYamaguchi, 2000.[@CIT0092]38.4%, 36.5%10,862,196RT-PCRHT29 or HT115 cell spiking--14 mL33 patients, 70 controls/BloodI--IVMathur, 2001.[@CIT0093]85%11,417,979RT-PCRLS 180 and C205; ATCC CL-187 and CCL-222 cell spiking--12 mL39 patients,13 controls (abnormal)/BloodI--IIIGuller, 2002.[@CIT0094]28%12,454,515qRT-PCR------167 patients, 25 controls/BloodI--IVIinuma, 2006.[@CIT0095]22%16,391,782qRT-PCRHT29 cell spikingCA19-910 mL46 patients, 23 controls/BloodI--IVLiu,2012.[@CIT0096]65.21%, 36.95%22,414,974CK20, CK19RT-PCRCell SpikingK-ras, p5320 mL35 patients, 23 controls/BloodI--IVNakamori, 1997.[@CIT0098]26%9,378,009CK20, CEA, CK19.Nested RT-PCR------62 patients, 12 controls/BloodI--IVHuang, 2003.[@CIT0097]35.5%, 48.4%, 51.6%12,684,893CK20, GCC.RT-PCR--CEA, CA1995 mL100 patients, 5 controls/BloodI--IIILiu, 2017.[@CIT0103]--28,418,917qRT-PCR--CEA5 mL69 patients, 23 controls//BloodI--IIILiu, 2013.[@CIT0104]23,150,200CK, CEA, CD133.qRT-PCR--CK19, CK2010 mL735 patients/BloodB--C DukesIinuma, 2011[@CIT0106]24.52%21,422,427CK20, CEA, CK19, CD133qRT-PCR------197 patients, 20 controls (benign diseases)/BloodB--C DukesShimada, 2012.[@CIT0100]63%22,267,181CEA, EPCAM.CellSearch, TRC methodDLD1 cell spiking--7.5 mL67 patients/BloodMetastaticSato, 2012.[@CIT0108]9.0±23.4%, 64.3%21,732,137CK20, CEA, Survivin.CD45 immuno magnetic beads + Ber-EP4 immuno magnetic beadsLovo cell spiking, Real-time RT-PCR--10 mL156 patients, 40 benign patients, 40 healthy/BloodA--D DukesShen, 2008.[@CIT0111]47.4%, 39.1%, 57.7%.18,845,519CK20,CEA, ProtM,Real-time RT-PCRCOLO 205, LS-174-T, CX 2, CX 94, HCT 116, HT 29, CaCo2 cell spikingPBGD10 mL129 patients, 47 controls/Blood0--IVSchuster, 2004.[@CIT0112]88%, 86%; 17%14,639,606CK19, CK20, MUC1, MUC2.Immunobead RT-PCRSW48, SW480, HT29, LIM-2412, LIM-1215, LIM-2099, LIM-2405, LIM-1899, LIM-2463 and LIM-1863 cell spiking--20 mL94 patients, 20 controls/BloodA--D DukesHardingham, 2000.[@CIT0099]20%10,719,724CK-19, CK-20, CEA, hTERT.Membrane arraysRT-PCR--4 mL72 patients, 30 controls/BloodI--IVWang, 2006.[@CIT0113]66.7%, 52.8%, 72.2%, 69.4%16,736,329CGM2 (CEACAM7)RT-PCRCACO-2 and HT-29 cell spiking--20 mL78 patients, 115 controls/BloodA--D DukesDouard, 2001.[@CIT0116]59%11,331,451CEACAM5, CEACAM7Immuno bead multiplex RT-PCR--HBB20 mL84 patients, 41 controls, 32 non CRC patients/BloodI--IVDouard, 2005.[@CIT0115]55%, 45%15,843,204EPCAM, EGFR.Immuno magnetic selection (IMS), multiplex RT-PCRT84, HT29, SW948 and SW1116 cell spikingCEA5 mL76 patients, 106 controls/BloodI--IVZieglschmid, 2007.[@CIT0107]88%, 12%.17,649,779EGFRRT-PCRImmunohistochemistry (IHC)CEA (45%), CK-19 (27%)5 mL38 patients, 38 controls/BloodB, C DukesDe luca, 2000.[@CIT0118](73%)10,778,975RT-PCR----3 mL16 patients, 23 controls/BloodAdvanced-stageClarke, 2003.[@CIT0119]12.5%12,527,944EGFR, HLMRT-PCRNorthern blotting, HT11C cell spiking--3 mL1 patients, 9 controls/BloodMetastaticFournier, 1999.[@CIT0120]100%10,446,991EGFR, Tenascin C.----5 mL41 patients, 40 controls/BloodI--IVGazzaniga, 2005.[@CIT0121]49%16,211,285PLS3RT-PCRFluorescent immunocytochemistryCEA--711 patients, 25 controls/BloodDukes A, B, C, and DYokobori, 2013.[@CIT0122]25%23,378,342PLS3, AQP5RT-PCRFluorescent Immuno cytochemistryCD45 (−)10 mL177 patients, 25 controls/BloodDukes A, B, C, and DSugimachi, 2014.[@CIT0123]-24,217,791CD45 magnetic bead depletionFISH ImmunofluorescentCEP8≥3 and7.5 mL45 patients, 25 controls/BloodI--IVShan, 2014[@CIT0131]55%25,109,507PKP3, AGR2.Bioinformatic analysis and RT-PCRGp5d, LoVo, DLD1, LS513, HT29, OJC4, OJC5, OJC6 cell spikingS100A16, S100A6, LGALS4, CLDN3.10 mL21 patients and controls/BloodIII--IVValladares-Ayerbes, 2008.[@CIT0124]40%, 81.8%18,801,625AGR2, LGR5.qRT-PCR----10 mL54 patients, 19 controls/BloodI--IVValladares-Ayerbes, 2012.[@CIT0126]84.9%, 90.5%22,605,983DCLK1, LGR5qRT-PCR----10 mL58 patients, 58 controls/BloodI--IVMirzaei, 2015.[@CIT0127]63.7%25,631,749LGR5mRNA ISH--EpCAM, CK8, CK18, CK19 Twist1, Vimentin, AKT2, SNAI1, CD45 (−)5 mL66 patients,/BloodI--IVWang, 2018.[@CIT0128]86.4%29,949,050CK20, Tyrosinase, PSA.RT-PCR, Nucleic acid sequence-based amplification (NASBA assay)HT-29 cell spiking, In vitro cell assay--2 mL12 patients, 8 controls/Blood--Burchill, 2002.[@CIT0132]--11,857,020MAGE-AElectrochemiluminescence (ECL), RT-PCRSequencing analysisuMAGE-A, M-A1, M-A3, M-A1210 mL12 patients, 20 controls/BloodI--IVMiyashiro, 2001.[@CIT0133]29%11,238,304DVL1Microarray and enzymatic chip array (WEnCA)IHCPSG2, TMPO, CD55, ELAVL4, PDX1, CTHRC1, CA9, TK1, UBE2C, FOXM1, PDE6D, PSAT1, CHRNB1,CEA,BMI CAP2, MMP13, OLFM4, PTTG1, MYC, MET, ENO2, MUC1, KRT19, BIRC5, HMGB1, KRT20, hTERT, GCNT1, NPM14 mL214 patients/BloodI--IIIHuang, 2013.[@CIT0134]55%24,129,181CD47Cellsearch--EPCAM, CD45 (−)20--30 mL72 patients/BloodI--IVSteinert, 2014.[@CIT0135]14%24,599,131CD44v9OncoQuickqRT-PCR--20 mL150 patients, 15 controls/BloodI--IVKatoh, 2015.[@CIT0136]40%25,550,556CK19, AGR2, CK8, CK9.CellSearchn--TSPAN8, LAD1, CK20, IGFBP5, GPX2, FABP1, S100A1,6 CK8, PRSS8, CDX1, CEACA,M5, AKR1C3, RARRES2, REG1A, IGFBP4, CD44, TRIM2, CXCL1, SATB2, NQO1, CK19, MAPT, IGFBP3, COL4A1, FCGBP, SLC6A8, CDH5, CDH17, EGFR, S100P, HOXB9, CDH1, MACROD1,30 mL142 patients, 30 controls/BloodMetastatic colorectal cancerMostert, 2015.[@CIT0125]66%25,655,581CK20, CEA, AGR2, MGB2, DLL4, EphA2, Her3, PDGFRαqRT-PCR----7.5 mL24 patients/BloodIII--IVBao, 2013.[@CIT0137]59%23,990,866CK-20, CEA, CK-19, hTERT.TM4SF3, CK19.Membrane arraysRT-PCR--4 mL157 patients, 80 controls/BloodI--IVWang, 2007.[@CIT0114]50%17,406,027RT-PCR--CEA, CK20, TACSTD1,10 mL28 patients, 19 controls/BloodI--IVXi, 2007.[@CIT0101]96.4%17,525,108DCLK1, LGR5, EpCAM, CK8, CK9, CK19, Vimentin, TwistqRT-PCR, IHC----10 mL78 patients and controls/BloodI--IVMirzaei, 2016.[@CIT0109]26,383,518CanPatrol CTC enrichment(ISH) assay--5 mL38 patients, 27 controls/BloodI--IVWu, 2015.[@CIT0110]67%25,909,322PSG2, ELAVL4, TK1, UBE2C, PDE6D, PSAT1, CHRNB1, BMI1, CAP2, MMP13, OLFM4, PTTG1, MYC, MET, MUC1, HMGB1, hTERT, BIRC5,Enzyme immunoassay test kit--CEA3 mL298 patients/BloodI--IIIChang, 2016.[@CIT0138]-27,701,415PI3Kα, Akt-2, Twist1 ALDH1antiCD45 specific antibodies (Dynabeads, Invitrogen)qRT-PCR and multiplex-PCR_8 mL78 patients, 20 controls/BloodI--IVNing, 2018.[@CIT0129]55%27,503,579CK19, MUC1, CD44, CD133, ALDH1CD45 Human MicroBeads (Miltenyi Biotec), enrichment of cytokeratin (Miltenyi Biotec)Flowcytometry, CellSearch, qRT-PCR, Cytomorphology, PC3, MDA-MB-231 and SKBR3 cell spiking_7.5 mL63 patients, 40 controls/BloodI--IIIBahnassy, 2019.[@CIT0139](55.6%), (46.0%), (44.4%), (41.3%) (41.3%)30,578,762CEACAM5, CK19, AGR2, LGR5Inertial microfluidics combined with droplet digital PCRqRT-PCR, HT-29 and LoVo cell spiking--9 mLPatients and controls/BloodAdvancedMethai, 2019.[@CIT0164]-31,304,099

Exosomes {#S0003-S2005}
--------

Some prognosis markers have nearly the same functional patterns as molecular markers related to CRC. Studies have reported on colorectal exosome prognostic markers such as ALIX (ALG 2-interacting protein X),[@CIT0140],[@CIT0141] Hsp60,[@CIT0142] Hsp70,[@CIT0141] CEA,[@CIT0143] ATP-binding cassette transporter G1 (ABCG1),[@CIT0144] copine III (CPNE3),[@CIT0145] and ΔNp73[@CIT0070] in cancer patients.

Tauro et al, used multiple isolation methods to detect known exosome markers such as ALIX, TSG101, HSP70, and other specific and novel markers listed in [Table 5](#T0005){ref-type="table"}.[@CIT0141] Chen et al, applied bioinformatic analysis for introduction of two panels and validated them.[@CIT0146] Chiba et al, reported that exosomes derived from CRC cell lines contain mRNA, microRNA, and natural antisense RNA as listed in [Table 5](#T0005){ref-type="table"}.[@CIT0071]Table 5The biomarkers which worked for prognostic of CRC in exosomeBiomarkerTechnique of exosome isolationTechnique of exosome validationTechnique of markers detection or validationRelated markerPatients (number/type)Patient stageAuthor/year:PMIDAlix----GSE37364, GSE10714, GSE4183, GSE18105, GSE4107, GSE9348, GSE8671, IHCPGK1, PKM, ANXA5, ENO1, HSP90AB1, MSN72 patients, 27 controls, and 98 sample (literature bioinformatic)I--IVValcz G, 2016.[@CIT0140]27,150,162ΔNp73UC-Exo\* centrifugation 120,000 and PVDF filterAcetylcholinesterase activity, flow cytometry quantification, transmission electron microscopy, Western blot analysisqRT-PCR, Cell culture and transfectionCEA69 patients and control tissues, HCT116 cell lines.I--IVSoldevilla, 2013.[@CIT0070]24,067,531Hsp60UC-ExoTEM AChEase:acetylcholinesterase assay, Western blotIHC, ELISA, immunogold electron microscopyHsc70, Alix, CD57, CD6857 patients and control tissues, 2 blood sampleI--IIICampanella, 2015.[@CIT0143]26,060,090RPL13A, HMBS, TBPUC-ExoBCA, Western blottingqRT-PCRmiR-21, miR-34, miR-143, miR-192, miR-215, miR-22WiDr, HCT-15, SW480 cell lines--Chiba, 2012.[@CIT0071]22,895,844TSAP6, CEAUC-ExoFlow Cytometry, Western blottingqRT-PCR, IHC, levels of circulating exosomes in plasma91 patients, 12 controls/tissue and bloodI--IVSilva, 2012.[@CIT0142]22,420,032Alix, TSG101, HSP70, CD9, CD81, ESCRT-III, VPS32C/CHMP4C, VAMP2, EFNB1, EFNB2, EPHA2--8, EPHB1--4, CTNNB1, TNIK, CRK, GRB2UC-Exo, DG-Exo: OptiPrep™ density gradient exosome, IAC-Exo: EpCAM immunoaffinity captureWestern blotting, EM: Electron microscopyGeLC--MS/MS (protein profiling)--LIM1863 cell line--Tauro, 2012.[@CIT0141]22,285,593BCL7C, EEF1G, RAB13, RSP3, TPT1, SCARB1, SCDUC-ExoA33-Exos and EpCAM-Exos (Dynabeads™), TEM, Western blotSRP02205476, SRP029880 (Microarray)--LIM1863 cell line--Chen, 2016.[@CIT0146]27,917,920CPNE3UC-ExoTEM, NTA, Western blottingCEA92 patients, 32 controls/BloodSensitivity of 67.5% and a specificity of 84.4%Sun, 2019.[@CIT0145]30,078,189ABCG1Polymer-based precipitation methodTEM, Zetasizer Nano ZSP, Western blotting,qRT-PCR, IHC, GSE1753749--Murine cell lineNamba, 2018.[@CIT0144]30,364,132[^4]

Risk of bias (quality) assessment {#S0003-S2006}
---------------------------------

All articles related to CTC (39 diagnosis-related and 57 prognosis-related) were assessed by NOS case-control guidelines as reported in [[Table S1]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=219699a.docx). Of the diagnosis-related articles (40% of the total), 43%, 43%, and 14% scored 7, 6, and 5, respectively. Of the prognosis-related articles (60% of the total), 49%, 31.5%, 14%, and 1.5% scored 7, 6, 5, and 4, respectively; and 4% could not to be scored.

All articles related to exosomes (Five diagnosis-related and nine prognosis-related) were assessed by the NOS case-control guidelines in [[Table S2]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=219699b.docx). Of the diagnosis-related articles (36% of total), 20%, 40%, and 40% scored 7, 6, and 5, respectively. Of the prognosis-related articles (64% of total), 67%, 22%, and 11% scored 7, 6, and 5, respectively. The 0--3 and 8--9 scores were not given out in these studies, so the NOS number varied from 4 to 7. About 99.3% of systematically imported articles scored over 5, 20% ofthe articless scored 5, and 79.7% scored 6 or 7.

Bioinformatics approach to systematic results {#S0003-S2007}
---------------------------------------------

This systematic search identified 66 CTC gene markers for the diagnosis of CRC, 65 CTC gene markers for prognosis with repetition, 10 exosome gene markers for diagnosis of CRC, and 35 exosome gene markers for prognosis as shown in [Tables 2](#T0002){ref-type="table"}--[5](#T0005){ref-type="table"}.

Protein--protein interaction network via STRING analysis {#S0003-S2008}
--------------------------------------------------------

In the gene network, biochemical functions and identified pathways were obtained from gene expression data, and the results are shown in [Figures 3](#F0003){ref-type="fig"} and [4](#F0004){ref-type="fig"} and supplementary [[Table S3]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=219699c.xlsx) (online resources). Surprisingly, the cellular components of exosomes and CTC highlight extracellular space, region and exosome, plasma membrane, and cell junction. Their molecular function highlights cell adhesion molecule binding and protein binding. Biological processes included regulation of cellular component movement, assembly, localization, organization, and response to external stimuli.Figure 3Network and enrichment analysis visualization. Combined screenshots from the STRING website, showing results obtained upon entering a set of 131 proteins suspected to be involved in circulating tumor cell markers. According on kmeans clustering has been selected, the corresponding protein nodes in three categories automatically highlighted in colors.Figure 4Network and enrichment analysis visualization. Combined screenshots from the STRING website, showing results obtained upon entering a set of 45 proteins suspected to be involved in Exosome markers. According on kmeans clustering has been selected, the corresponding protein nodes in three categories automatically highlighted in colors.

Gene ontology {#S0003-S2009}
-------------

The results of EnrichR web tools in supplementary [Table S4](https://www.dovepress.com/get_supplementary_file.php?f=219699d.xlsx) (online resources) can be used to accurately understand the molecular pathways. The common pathways in biomarkers such as proteoglycans in cancer, focal adhesion pathways in cancer, integrin, Rap1, MAPK signaling pathways, angiogenesis, p53 pathways, and viral processes were similar and related to cancer.

Discussion {#S0004}
==========

CRC is a common malignancy that often has a poor prognosis.[@CIT0147] The tumor microenvironment contributes to its progression[@CIT0148] and cross-talk between cancer cells and exosomes play a critical role in this dynamic network.[@CIT0149] Their identification and characterization are important steps to improve understanding of cellular and molecular cancer metastasis. Tracking of tumor-associated molecular markers in the blood can be used to assess the presence of residual disease, recurrence, and resistance.[@CIT0150] This systematic review highlights new trends and approaches in CRC biomarker discovery using CTC and exosomes.

Evidence related to diagnosis of CRC by means of CTC markers was addressed in 38 articles ([Table 2](#T0002){ref-type="table"}) and 54 articles discussed prognosis of CRC using CTC markers ([Table 4](#T0004){ref-type="table"}). Only 14 articles examined exosomes, five about diagnosis and nine about prognosis ([Tables 3](#T0003){ref-type="table"} and [5](#T0005){ref-type="table"}). Our results show that the most common markers introduced in CTCs were CEA (35 of 94 studies) and CK20 (33 of 94 studies), especially using quantitative real-time polymerase chain reaction. Most markers investigated for exosomes, in addition to CD9, CD81, ALIX, and TSG101, were including EPCAM and HSP, especially using ultracentrifugation. Comparison of 131 CTC markers and 45 exosomes markers showed only three common markers (CEA, CD9, and EPCAM) on the gene list as diagnostic and prognostic biomarkers.

A half-century-old investigation of CEA in CRC was the first step in the identification of a much larger family of 12 CEACAMs.[@CIT0151],[@CIT0152] Gene encoding CEA is a member of the immunoglobulin supergene family[@CIT0153] that plays a role in cell adhesion and tumor progression,[@CIT0154] even in protecting the colon from microbial infection.[@CIT0155] CEA is involved in the metastatic cascade process through positive regulation of cell migration and invasion;[@CIT0156]--[@CIT0158] thus, the monitoring of CEA as a cost-effective and frequent indicator of recurrence of CRC has been investigated for years.[@CIT0159]

Integrin on tumor exosomes may play an important role in modulating organ-specific metastasis in cancer progression. CD9 is a member of the tetraspanin superfamily commonly detected in all types of exosomes involved in pathophysiologic processes such as cellular adhesion, growth, motility, cell--cell fusion, signal transduction, and tumor metastasis.[@CIT0160]

EPCAM is a membranous glycoprotein that is a CSC marker in tumor cells in the basolateral surface of most normal epithelial tissue and its role is to connect cells by means of calcium. The expression of this marker increases in benign and malignant tumors that arise from epithelial tissue.[@CIT0161] The first step in metastasis is the separation of cancerous cells from primary tumors. CEA, CD9, and EPCAM are closely correlated with tumor progression as a poor prognostic factor and is required for the survival of CTCs in some cancers.[@CIT0162] Taken together, it appears that the signature of the CTC and exosome biomarkers are similar and follow common pathways; thus, exosomes can be applied as alternative tools for guiding better molecular pathology in the fight against cancer.

Precision medicine is changing clinical practice by tailoring treatment based on an individual's genetic makeup. Recent studies have shown that CTC and circulating tumor DNA provide complementary information and the use of both approaches to study tumor metastasis is warranted.[@CIT0163] CTC and exosomes can pave a path as diagnostic and prognostic procedures using the heterogeneity of tumor sites as they are released into the blood from live origins and can be analyzed at the DNA, RNA, and protein levels. It is undeniable that more investigation is needed to compare them, especially for cancer patients.

Various CTC isolating techniques each have its own advantages and disadvantages as to their CTC capture capacity and subgrouping of CTCs based on various markers. Similar problems also exist for exosomes, with a lack of a proven rapid and high-yield approach for extracting exosomes for downstream analysis.[@CIT0164] Microfluidic devices and bioinformatics analysis might play an important role in solving the current shortcomings of the liquid biopsy concept. Microfluidics, by using inertial focusing/hydrodynamics (laminar flow in microchannels) and applying spiral, acoustic, electrophoretic, and electromagnetic features passively separate CTCs and exosomes from the other background calls.[@CIT0165] Immobilizing specific antibodies either on micro-posts or in a herringbone design against their marker might be useful; it is easy to explore and yields quantitative readouts with high sensitivity, low cost, and minimal sample handling. Finally, although the potential clinical utility of these techniques is clear, more effort is needed to use the full potential of liquid biopsy in clinical settings.[@CIT0166]

Future perspectives {#S0005}
===================

Currently, isolation and purification of tumor-derived exosome in a worm bag of EVs is technically cumbersome and also isolation of CTCs has its own limitations. Therefore, combined use of these two biomarkers together as a liquid biopsy requires large-scale clinical trials. Microfluidic devices and bioinformatics analysis might play an important role in solving the current shortcomings of the liquid biopsy. Additionally, cross talking of CTCs and tumor-derived exosomes in a tumor microenvironment should become a heated question in exploring the premetastatic niche. As such, more research is needed on CTCs and exosome's overlapping molecular pathways to determine more effective biomarker signatures of CRC, especially in the metastatic form. Figure 1Design of PRISMA flow diagram explaining details of our search process was applied during the article selection for circulating tumor cell.Figure 2Design of PRISMA flow diagram explained details of our search process that applied during the article selection for Exosome.
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[^1]: **Abbreviation:** CTC, Circulating tumor cells.

[^2]: **Abbreviations:** RT-PCR, real-time polymerase chain reaction; Controls, healthy volunteer/donors; I--IV, TNM classification of malignant tumors (TNM); A--D Dukes, Dukes staging system is a classification system for colorectal cancer.

[^3]: **Abbreviations:** TEM, transmission electron microscopy; NTA, nanoparticle tracking analyzer; PEG, polyethylene glycol polymer; ELISA, enzyme-linked immunosorbent assay; SEM, scanning electron microscope; DLS, dynamic light-scattering.

[^4]: **Abbreviation:** UC-Exo, ultracentrifugation exosome.
